Hypertrophic cardiomyopathy (HCM) is a disorder of the heart due to dysfunction of the sarcomeres in cardiac muscle cells (myocytes). Sarcomeres are cellular structures that are critical in myocyte contraction. The sarcomere dysfunction in HCM can lead to hypertrophy (thickening) of the heart. HCM can be due to a number of heritable genetic defects affecting […]
Myasthenia gravis is a rare chronic autoimmune disorder in which the immune system produces antibodies that prevent acetylcholine from binding with acetylcholine receptors, ultimately resulting in muscle contraction. Interventions of Interest: Efgartigimod (Argenx, Halozyme Therapeutics, and Zai Lab) Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.) For more information, please contact Maggie O’Grady, Program Manager, at mogrady@icer.org. View the […]
Atopic dermatitis is a chronic relapsing skin condition associated with dry skin and itching. It is characterized by acute flare-ups of pruritic lesions over dry skin. Atopic dermatitis is a subset of the broad classification of eczema. It is the most common skin disease in children, with 50% of patients experiencing onset of disease within […]
In June 2018, ICER announced its intention to assess the comparative clinical effectiveness and value of canakinumab (Novartis) for cardiovascular risk reduction in people with atherosclerosis. However, in October 2018, when the Food and Drug Administration declined to approve canakinumab’s expanded indication for atherosclerotic cardiovascular disease, ICER announced it would no longer proceed with its value assessment. […]
Opioids are used to treat cases of acute and chronic pain that arise from a variety of causes, ranging from trauma to palliative care for advanced illness. Every year, 100 million people in the United States suffer from pain, 9-12 million of whom have chronic or persistent pain. Although opioid therapy is an important component […]
ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer. During the public meeting the Midwest CEPAC voted on key questions related to the clinical effectiveness and value of the PARP inhibitors in two key populations: women receiving maintenance therapy for recurrent disease that […]
ICER released the results of its initial analyses to inform public debate of pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19. Working with external academic partners, ICER has developed ICER-COVID models comprising two alternative pricing paradigms for COVID-19 treatments: 1) “cost recovery” for the manufacturer, representing an estimate based on peer-reviewed methods […]
ICER is assessing the comparative clinical effectiveness and value of voclosporin (Lupkynis™, Aurinia Pharmaceuticals) and belimumab (Benlysta®, GlaxoSmithKline) for the treatment of lupus nephritis. Voclosporin was approved for lupus nephritis in 2021, and belimumab is seeking a label expansion for the treatment of lupus nephritis. The evidence suggests belimumab and voclosporin represent important new treatment […]
Disparities across racial and socioeconomic lines in the utilization of health care services and in patient outcomes continue to plague healthcare systems in the U.S. Policies to address health care disparities have varied, including steps to increase access to health insurance coverage at both the state and federal levels, policies aimed at increasing the diversity […]
ICER completed a Technology Assessment of cardiac nuclear imaging for the public meeting of the Washington State Health Technology Assessment Program’s Clinical Committee. Date of review: September 2013 Intervention of interest: Cardiac nuclear imaging Final Documents Below you will find the final documents from the assessment review process:
Recent Comments